Is Arcadia Biosciences going out of business?

Arcadia Biosciences, Inc. (RKDA) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

Arcadia Biosciences, Inc. (RKDA) scores 12 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 85.89% (YoY) - Heavy dilution suggests continuous equity raises; survival depends on external capital.

Five questions, kept separate

Survival - Critical

3-6 mo of estimated runway from 2026-06-30, based on $4.2M of cash and short-term investments against $11.1M of annual burn. Adjusted shares outstanding increased 85.9% over the comparison year.

Business quality - Poor

-80.2% operating margin and -233.8% FCF margin produce a poor Business Quality assessment.

Trajectory - Deteriorating

Revenue weakened 7.6%; operating margin weakened 30.8pp; FCF margin improved 199.1pp. The TTM window includes a mixed-basis Q4 estimate.

Valuation - Extreme expectations

-928.5% normalized FCF yield supports an extreme expectations Valuation assessment on the ttm basis.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 85.89% (YoY) - Heavy dilution suggests continuous equity raises; survival depends on external capital.
• ROE quality: -1910.74%
• Filing event risk: Going-Concern Warning (-8 pts)
• Asset Efficiency: 0.81x
• Revenue CAGR (3Y): -13.16%
• Revenue growth YoY: -0.82% (Industrial YoY)
• Net Debt / FCF: 0.0y
• Return on Assets: -205.24%
• Price / Sales: 0.2x (see Valuation)
• Price / Earnings: Unprofitable (see Valuation)
• FCF margin: -233.78%
• Cash Burn Deceleration: 1.64% QoQ improvement

Read from filings through 2026-08-13.

Price as of 2026-09-12.